Novartis Takes Rights to Conatus NASH Drug

(c) Novartis
(c) Novartis

Swiss pharma company Novartis has exercised an option that gives it global development and commercialization rights to a drug being developed by US biotech Conatus Pharmaceuticals to treat non-alcoholic steatohepatitis (NASH), a progressive form of fatty liver disease.

Once all required antitrust approvals have been received, Novartis will pay a $7 million fee to Conatus for emricasan, an investigational, first-in-class, oral, pan-caspase inhibitor that has shown potential in treating NASH with advanced fibrosis and cirrhosis. Novartis said the collaboration could expand treatment options for people in various stages of fatty liver disease where no approved medicines currently exist.

Under the alliance, Conatus will perform multiple Phase IIb trials. If results are successful, Novartis will conduct Phase III studies of emricasan as a single treatment as well as developing therapies in combination with its own Farnesoid X receptor (FXR) agonists.

FXR agonists have been shown to address three of the most important aspects of NASH progression by reducing fat, inflammation and fibrosis in the liver. Novartis has two non-bile acid FXR agonists in Phase II clinical trials, both of which have Fast Track designation from the US Food and Drug Administration (FDA) for NASH with liver fibrosis. The FDA has also given Fast Track status for developing emricasan in patients with NASH cirrhosis.

The move follows another NASH collaboration that Novartis announced last month. Under this agreement, a combination of Allergan’s cenicriviroc and Novartis’ lead FXR agonist will undergo Phase IIb trials.

According to Novartis, NASH is expected to be the primary cause of liver transplants in the US by 2020.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.